×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VIRX – viracta therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VIRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
01:35 pm
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.
Medium
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.
11/13
07:00 am
virx
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
04:43 pm
virx
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma [Yahoo! Finance]
High
Report
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma [Yahoo! Finance]
11/6
04:30 pm
virx
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
Medium
Report
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
10/22
09:59 am
virx
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Low
Report
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
9/3
07:00 am
virx
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
High
Report
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Date
Time
Symbol
Company Name
Action
%Chg
3/7/2024
04:05 pm
virx
viracta therapeutics, inc.
MISS
Report
5.0%
viracta therapeutics, inc.
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: